Comparison of melanoma antigens in whole tumor vaccine to those from IIB-MEL-J cells

J. M.C. McGee, M. R. Patten, K. F. Malnar, J. A. Price, J. S. Mayes, G. H. Watson

Research output: Contribution to journalArticle

Abstract

Immunotherapy for melanoma shows promise. Our previous whole tumor (WT) vaccine was noted to have positive clinical effects. We have now developed a new, safer melanoma vaccine that is derived from IIB-MEL-J tissue culture (TC) cells. In this study, we compare by Western blot analyses the antigens in the WT vaccine to antigens in the TC vaccine. Sera from 12 WT vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 controls served as a source of antibodies to investigate potential antigens in the vaccines. Three major antigenic peptides with approximate molecular weighs of 46, 40, and 36 kDA were present in both vaccines, while two other antigenic peptides with approximate molecular weighs of 68 and 48 kDA were present only in the TC vaccine. The reaction was similar between the patients who received the WT vaccine and those who did not receive the vaccine. Some of the individuals who did not have melanoma showed some reaction, but not to the extent of the melanoma patients. The intensity of immunostaining was greater for the TC vaccine when compared to the WT vaccine, indicating that these proteins are in a higher concentration in the TC vaccine. This new vaccine from IIB-MEL-J tissue culture cells provides a higher yield and a much more consistent source of potentially clinically relevant antigens without risk of infection or contamination by other irrelevant materials.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume14
Issue number3
DOIs
Publication statusPublished - 1 Jan 1999

    Fingerprint

Keywords

  • Antibodies
  • Melanoma antigens
  • Melanoma tissue culture cells
  • Melanoma vaccines
  • Western blot

Cite this